SCM
MDGL icon

Silvant Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Silvant Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,213
Closed -$87K – 378
2022
Q2 		$87K Hold
1,213
– – 0.02% 224
2022
Q1 		$119K Hold
1,213
– – 0.02% 214
2021
Q4 		$103K Sell
1,213
-78
-6% -$6.41K 0.02% 221
2021
Q3 		$103K Hold
1,291
– – 0.02% 220
2021
Q2 		$126K Hold
1,291
– – 0.02% 215
2021
Q1 		$151K Hold
1,291
– – 0.03% 202
2020
Q4 		$144K Hold
1,291
– – 0.02% 209
2020
Q3 		$153K Hold
1,291
– – 0.03% 193
2020
Q2 		$146K Hold
1,291
– – 0.03% 194
2020
Q1 		$86K Hold
1,291
– – 0.02% 205
2019
Q4 		$118K Hold
1,291
– – 0.02% 213
2019
Q3 		$111K Buy
1,291
+625
+94% +$58.6K 0.02% 216
2019
Q2 		$70K Hold
666
– – 0.01% 261
2019
Q1 		$83K Hold
666
– – 0.01% 241
2018
Q4 		$75K Hold
666
– – 0.02% 243
2018
Q3 		$143K Buy
666
+185
+38% +$46.4K 0.02% 212
2018
Q2 		$135K Buy
+481
New +$84.5K 0.02% 218

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silvant Capital Management's MDGL Position: Q3 2022 in Review

Silvant Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2022, closing a stake of 1,213 shares — an estimated $87K sold.

Silvant Capital Management first reported a position in MDGL in Q2 2018 and held it in 17 quarters. The position peaked at $153K in Q3 2020. 135 funds tracked by Wall St. Rank hold MDGL as of Q3 2022.

  • Silvant Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Silvant Capital Management sold 1,213 Madrigal Pharmaceuticals shares in Q3 2022, an estimated $87K.
  • Silvant Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 17 quarters.
  • Silvant Capital Management's Madrigal Pharmaceuticals position peaked at $153K in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2022.

Based on Silvant Capital Management's 13F filing for Q3 2022, filed 9 Nov 2022.